ArticleJHEP reports : innovation in hepatology2025
Randomized phase II study comparing two doses of regorafenib in second-line treatment for advanced hepatocellular carcinoma.
Keisuke Koroki et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it